Home › Modalities › Peptide
Peptide (14 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 8 | Phase 1 | 10 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 3 | Phase 3 | 3 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 3 | Phase 3 | 5 |
| ELTX | Elicio Therapeutics | Oncology | 3 | Phase 2 | 6 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 4 | Phase 2 | 4 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+2 Rare | 1 | Approved | 14 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | 1 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | 9 |
| NGEN | NervGen Pharma | Neurology | 2 | Phase 1 | 3 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 12 | Approved | 13 |
| SLS | SELLAS Life Sciences Group | Oncology | 5 | Phase 3 | 9 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology | 1 | Approved | 3 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 2 | Phase 3 | 8 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 1 | Approved | 4 |
No companies match.